

12th November 2018

(1) BSE Ltd
Listing Department,
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai 400 001

(2) National Stock Exchange of India Ltd
Listing Department
Exchange Plaza, 5th floor,
Plot no. C/1, G Block,
Bandra Kurla Complex,
Bandra (East), Mumbai - 400 051

Scrip Code: 500087

Scrip Code: CIPLA EQ

(3) SOCIETE DE LA BOURSE DE LUXEMBOURG
Societe Anonyme
35A Boulevard Joseph II,
L-1840 Luxembourg


Dear Sir/Madam,

Please find enclosed Press Release dated 12th November, 2018.

Kindly acknowledge the receipt.

Thank you,

Yours faithfully,
For Cipla Limited



Ashish Chauhan
Senior Manager - Corporate Secretarial

Encl: as above

Prepared by: Juzer Masta



Press Release

Cipla receives final approval for generic version of Roche's Valcyte® (Valganciclovir Tablets 450mg)

Mumbai, India, November 12, 2018: Cipla Limited ("Cipla") today announced that it has received final approval for its Abbreviated New Drug Application (ANDA) for Valganciclovir Tablets 450mg from the United States Food and Drug Administration (US FDA).

Cipla's Valganciclovir Tablets 450mg is AB-rated generic therapeutic equivalent version of Roche's Valcyte®. It is a deoxynucleoside analogue cytomegalovirus (CMV) DNA polymerase inhibitor indicated for use in the treatment of CMV retinitis in patients with acquired immunodeficiency syndrome (AIDS) and prevention of CMV disease in kidney, heart, and kidney-pancreas transplant patients at high risk.

According to IQVIA (IMS Health), Valcyte® and its generic equivalents had US sales of approximately \$79M for the 12-month period ending September 2018. The product is available for shipping immediately.

About Cipla:

Established in 1935, Cipla is a global pharmaceutical company focused on agile and sustainable growth, complex generics, and deepening portfolio in our home markets of India, South Africa, North America, and key regulated and emerging markets. Our strengths in the respiratory, anti-retroviral, urology, cardiology and CNS segments are well-known. Our 44 manufacturing sites around the world produce 50+ dosage forms and 1,500+ products using cutting-edge technology platforms to cater to our 80+ markets. Cipla is ranked

3rd largest in pharma in India (IQVIA MAT Sept'18), 3rd largest in the pharma private market in South Africa (IQVIA YTD Aug'18), and is among the most dispensed generic players in the US. For over eight decades, making a difference to patients has inspired every aspect of Cipla's work. Our paradigm-changing offer of a triple anti-retroviral therapy in HIV/AIDS at less than a dollar a day in Africa in 2001 is widely acknowledged as having contributed to bringing inclusiveness, accessibility and affordability to the centre of the movement. A responsible corporate citizen, Cipla's humanitarian approach to healthcare in pursuit of its purpose of 'Caring for Life' and deep-rooted community links wherever it is present make it a partner of choice to global health bodies, peers and all stakeholders. For more, please visit www.cipla.com, or click on [Twitter](#), [Facebook](#), [LinkedIn](#).

For queries, please contact:

Corporate Communications

Heena Kanal

E-Mail: CorpComm@cipla.com

Investor Relations

Naveen Bansal

E-Mail: Investor.Relations@cipla.com